Feel whole again
The only device able to restore sensations to limbs
By stimulating the peripheral nervous system, our unique technology revives communication between nerve damaged areas and the brain to lower risks of diabetic neuropathy complications.
Sensory feedback is restored
Healthy nerve signals restore protective foot sensations to lower risk of falls, ulcers and amputation.
Electrodes are implanted
in the nerve
The intra-nerve electrode array is implanted inside the peripheral nerve accessing all the sensory fibers to reconstruct healthy nerve signals to the brain.
How our closed loop system works
Sensors under the diabetic foot
Wearable sensors detect information of touch and movement from the foot and transmit it wirelessly to electrodes implanted inside the nerve.
Diabetic Neuropathy
affects millions of patients globally
Today, no existing solutions address the core cause of diabetic neuropathy complications; a disrupted sensory feedback loop.
Sensars is the only technology designed to completely restore sensory feedback to the extremities with high specificity and coverage.
How diabetic neuropathy works
How we reduce risks of complications
People worldwide with diabetic neuropathy risk losing sensations in feet
268 Million
Cost to healthcare each
year in US & EU
$73B
Our Partners
We have established deep partnerships with the world's most prestigious institutions, clinics and accelerators.
We have also been granted numerous global awards for our breakthrough technology.
Clinical Partnerships
.png){kind=logo}
Academic & Industrial Partners
Grants & Awards
Latest Awards & Features
Masschallenge Silver Award Winner '22
MIT Under 35
News
SENSY: Groundbreaking Technology for Diabetic Neuropathy
Neurotech Reports highlights Sensars as an emerging company with groundbreaking technology for the treatment of painful diabetic neuropathy. Read More >
.png)
Sensars gets funding of €1.1M to advance its SENSY product
Lausanne, Munich, May 2024 – Sensars, a pioneering leader in neuromodulation technology, is proud to announce significant advancements in its mission to revolutionize the treatment of chronic pain and sensory loss. Read More >
Sensars coordinates a €3 million grant to test its bionic prosthetics
Sensars has received a 3 million EUR grant as part of the European Union’s Horizon Research and Innovation program. The startup will coordinate and use the funds to further develop and test its product - the neuroprosthetic system. Read More >
Top '20 Most Innovative Companies to Watch, 2022
Sensars Named In Business Worldwide Magazines' Top '20 Most Innovative Companies to Watch, 2022. Read More >
Sensars receives FDA Breakthrough Device Designation
Two Swiss start-ups have been granted FDA Breakthrough Device Designation recently: AMF for its Sigi Insulin Management system and Sensars for its system providing sensory feedback for those with limb loss to improve prosthesis function. Read More >
Looking Ahead
Neurotech of the future
Our neurotechnology creates countless new possibilities in the future, from prosthetic control to obesity & depression treatment & beyond.